{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:26:44Z","timestamp":1791084404708,"version":"4.1.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Viral infections remain a major cause of morbidity in patients with immunodeficiency, such as recipients of hemopoietic stem cell transplantation. Adoptive transfer of donor-derived virus-specific cytotoxic T lymphocytes is a strategy to restore virus-specific immunity to prevent or treat viral diseases and has been tested in the clinical setting for more than 20 years. Several different groups have used expanded virus-specific T-cell products specific for one or multiple viruses to both reconstitute antiviral immunity after transplantation and to treat active viral infections. Response rates are encouraging, although resistance has been seen when the infused cell population has had restricted specificity or has targeted antigens expressed in donor-infected but not virally infected recipient cells. The goal of current trials is to make this approach more broadly applicable using more rapidly available products from the donor, such as directly selected or briefly expanded cells or closely matched banked cells.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.342","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T10:51:13Z","timestamp":1386327073000},"page":"342-347","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["T-cell therapy for viral infections"],"prefix":"10.1182","volume":"2013","author":[{"given":"Helen E.","family":"Heslop","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Leen","sequence":"additional","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703015201700_B1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2019111703015201700_B2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.coi.2009.02.010","article-title":"Adoptive transfer of virus-specific and tumor-specific T cell immunity","volume":"21","author":"Berger","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"2019111703015201700_B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri1526","article-title":"Cellular immunotherapy for viral infection after HSC transplantation","volume":"5","author":"Moss","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"2019111703015201700_B4","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"issue":"26","key":"2019111703015201700_B5","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"2019111703015201700_B6","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/blood-2009-03-213256","article-title":"Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes","volume":"114","author":"Hanley","year":"2009","journal-title":"Blood"},{"key":"2019111703015201700_B7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in humans: lessons from Epstein-Barr virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"2019111703015201700_B8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2003-07-2449","article-title":"Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications","volume":"103","author":"Leen","year":"2004","journal-title":"Blood"},{"key":"2019111703015201700_B9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood-2012-05-430413","article-title":"Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation","volume":"121","author":"Gerdemann","year":"2013","journal-title":"Blood"},{"key":"2019111703015201700_B10","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/TP.0b013e31823328c0","article-title":"BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses","volume":"92","author":"Blyth","year":"2011","journal-title":"Transplantation"},{"key":"2019111703015201700_B11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3109\/14653249.2012.663486","article-title":"Clinical-grade varicella zoster virus-specific T cells produced for adoptive immunotherapy in hemopoietic stem cell transplant recipients","volume":"14","author":"Blyth","year":"2012","journal-title":"Cytotherapy"},{"key":"2019111703015201700_B12","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"key":"2019111703015201700_B13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CJI.0b013e318213cb90","article-title":"Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation","volume":"34","author":"Zandvliet","year":"2011","journal-title":"J Immunother"},{"key":"2019111703015201700_B14","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2003-05-1433","article-title":"Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy","volume":"105","author":"Trivedi","year":"2005","journal-title":"Blood"},{"key":"2019111703015201700_B15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.20040613","article-title":"Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers","volume":"202","author":"Cobbold","year":"2005","journal-title":"J Exp Med"},{"key":"2019111703015201700_B16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"key":"2019111703015201700_B17","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood"},{"key":"2019111703015201700_B18","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"2019111703015201700_B19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111703015201700_B20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/14653249.2012.662769","article-title":"The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation","volume":"14","author":"Sellar","year":"2012","journal-title":"Cytotherapy"},{"key":"2019111703015201700_B21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"2019111703015201700_B22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"key":"2019111703015201700_B23","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"key":"2019111703015201700_B24","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet"},{"key":"2019111703015201700_B25","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"key":"2019111703015201700_B26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"2019111703015201700_B27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"2019111703015201700_B28","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V97.4.835","article-title":"An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs","volume":"97","author":"Gottschalk","year":"2001","journal-title":"Blood"},{"key":"2019111703015201700_B29","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"key":"2019111703015201700_B30","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"key":"2019111703015201700_B31","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"2019111703015201700_B32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00262-009-0789-1","article-title":"A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation","volume":"59","author":"Uhlin","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"2019111703015201700_B33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019111703015201700_B34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/CJI.0b013e31826e35f6","article-title":"Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines","volume":"35","author":"Meij","year":"2012","journal-title":"J Immunother"},{"key":"2019111703015201700_B35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703015201700_B36","first-page":"223","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells after allogeneic hematopoietic stem cell transplant [abstract]","volume":"120","author":"Gerdemann","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111703015201700_B37","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"2019111703015201700_B38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2141.2011.08579.x","article-title":"Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease","volume":"154","author":"Qasim","year":"2011","journal-title":"Br J Haematol"},{"key":"2019111703015201700_B39","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"key":"2019111703015201700_B40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/TP.0b013e3181d7c424","article-title":"Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up","volume":"90","author":"Haque","year":"2010","journal-title":"Transplantation"},{"key":"2019111703015201700_B41","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/cis625","article-title":"Rapid salvage treatment with virus-specific T cells for therapy-resistant disease","volume":"55","author":"Uhlin","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/342\/1250406\/bep00113000342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/342\/1250406\/bep00113000342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:02:05Z","timestamp":1573959725000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/342\/20829\/Tcell-therapy-for-viral-infections"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.342","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}